Clinical overview of leukocyte adhesion and migration: Where are we now?

Seminars in Immunology

Volumn 14, Issue 2, 2002, Pages 133-140

  Marshall, Diane ^a   Haskard, Dorian O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adhesion molecule; Chemokine; Human; Polymorphism; Treatment

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ALPHA4 INTEGRIN; ANTEGRAN; BETA1 INTEGRIN; BETA2 INTEGRIN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CYTOKINE ANTIBODY; EFALIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 8; INTERLEUKIN 8 ANTIBODY; LIGAND; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SPLAT1; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; NITROBENZENE DERIVATIVE; PROBUCOL SUCCINATE; RECEPTOR BLOCKING AGENT; SELECTIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; PADGEM PROTEIN;

ARTICLE; CELL INTERACTION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG INDICATION; DRUG RESEARCH; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; NONHUMAN; PROTEIN EXPRESSION; CELL ADHESION; CELL MOTION; GENETICS; IMMUNOLOGY; LEUKOCYTE; LEUKOCYTE ADHESION DEFICIENCY; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; REVIEW;

CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; E-SELECTIN; HUMANS; INTEGRINS; LEUKOCYTE-ADHESION DEFICIENCY SYNDROME; LEUKOCYTES; LIGANDS; P-SELECTIN; RECEPTORS, CHEMOKINE;

EID: 0036024111     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.2001.0350     Document Type: Article

References (78)

1. Interactions between cancer cells and the endothelium in metastasis
2. Chemokines and the molecular basis of cancer metastasis
3. Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells
4. Circulating adhesion molecules in disease
5. Four soluble adhesion molecules and coronary heart disease: Prospective study and meta-analysis
6. Nuclear medicine imaging in infection and inflammation
7. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis
8. Use of a radiolabeled monoclonal antibody against E-selectin for imaging endothelial activation in rheumatoid arthritis
9. Visualizing E-selectin in the detection and evaluation of inflammatory bowel disease
10. 99m Tc-E-selectin binding peptide for imaging acute osteomyelitis in a novel rat model
11. Specific targeting of activated endothelium in rat adjuvant arthritis with a 99mTc-radiolabeled E-selectin-binding peptide
12. Imaging of vascular injury with 99mTc-labeled monoclonal antiplatelet antibody S12: Preliminary experience in human percutaneous transluminal angioplasty
13. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells
14. Uptake of indium-111-anti-intercellular adhesion molecule-1 monoclonal antibody in the allografted rat lung during acute rejection
15. 123Iodine-labelled anti-VCAM-1 antibody scintigraphy in the assessment of experimental colitis
16. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: Their quantitative definition and relation to leukocyte dysfunction and clinical features
17. Leukocyte adhesion molecules deficiency: Its structural basis, pathophysiology and implications for modulating the inflammatory response
18. Leukocyte adhesion deficiency type 1 (LAD-1)/Variant: A novel immunodeficiency syndrome characterised by dysfunctional β2 integrins
19. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional β2 integrins Mac-1 and LFA-1
20. A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by beta1 and β2 integrins
21. Leukocyte adhesion deficiency II-from A to almost Z
22. Evidence that CD31, CD49b and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants
23. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: Identification of chemokine and HIV-1-blocking human antibodies
24. DNA polymorphisms in adhesion molecule genes: A new risk factor for early atherosclerosis
25. An HphI polymorphism in the E-selectin gene is associated with premature coronary artery disease
26. E-selectin is a susceptibility gene for systemic lupus erythematosus (SLE)
27. The P-selectin gene is highly polymorphic: Reduced frequency of the Pro715 allele carriers in patients with myocardial infarction
28. Polymorphisms of the P-selectin gene and risk of myocardial infraction in men and women in the ECTIM extension study
29. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease
30. A high frequency African coding polymorphism in N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya
31. Interercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: Association with risk and severity
32. Intercellular adhesion molecule-1 gene polymorphisms in Behçet's disease
33. Multiple sclerosis: The increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469
34. Intercellular adhesion molecule-1 gene polymorphisms in Behçet's disease
35. Association between type 1 diabetes age-at-onset and intercellular adhesion molecule-1 (ICAM-1) gene polymorphism
36. The -403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma
37. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis
38. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES
39. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2- 64I) in sarcoidosis in a Japanese population
40. Genetic polymorphisms of CC chemokine receptor 3 in Japanese and British asthmatics
41. CC chemokine receptor 5 polymorphism in rheumatoid arthritis
42. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5
43. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis
44. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction
45. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis
46. Polymorphism in the fractalkine receptor CXC3CR1 as a genetic risk factor for coronary artery disease
47. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis
48. Single amino acid residues in the E- and P-selectin epidermal growth factor domains can determine carbohydrate binding specificity
49. The S128R polymorphism of E-selectin mediates neuraminidase-resistant tethering of myeloid cells under shear flow
50. A functional analysis of a natural variant of intercellular adhesion molecule-1 (ICAM-1Kilifi)
51. Differential binding of clonal variants of Plasmodium falciparum to allelic forms of intercellular adhesion molecule 1 determined by flow adhesionassay
52. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
53. Pharmacology of selectin inhibitors in ischemia/reperfusion states
54. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischaemia reperfusion injury in cats
55. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
56. Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine
57. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease
58. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
59. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study)
60. Anti-CD54 (Intercellular adhesion molecule-1; ICAM-1) monoclonal antibody therapy in refractory rheumatoid arthritis
61. Induction by persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis
62. A phase I/II open label study of the safety and efficacy of an anti- ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis
63. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group
64. The pathophysiologic role of α4 integrins in vivo
65. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
66. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS
67. Results of a double-blind, randomized, placebo-controlled, phase II trail of Antegran (natalizumab) in subjects with relapsing multiple sclerosis
68. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease
69. A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to a α4 integrin (Antegran TM) in moderate to severely active Crohn's Disease
70. LDP-02 (Millenium)
71. Nitrobenzene compounds inhibit expression of VCAM-1
72. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1
73. CCR1-specific non-peptide antagonist: Efficacy in a rabbit allograft rejection model
74. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection
75. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
76. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
77. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions
78. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells